Back to Search
Start Over
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
- Source :
- Cancers, Vol 12, Iss 3021, p 3021 (2020), Cancers, Volume 12, Issue 10
- Publication Year :
- 2020
-
Abstract
- The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61<br />80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8&ndash<br />7.8)<br />in second-line treatment, 7.7 months (95% CI: 2.8&ndash<br />11.0)<br />in third-line, 3.4 months (95% CI: 2.3&ndash<br />not reached (NR))<br />and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2&ndash<br />NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.
- Subjects :
- musculoskeletal diseases
advanced breast cancer
Neoplasm metastasis
T-DM1
Metastase
Trastuzumab
chemotherapy
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
HER2/neu
lcsh:RC254-282
Article
metastatic
HER2 c-erbB2
trastuzumab
pertuzumab
Brustkrebs
Breast neoplasms
Drug therapy
ddc:610
Chemotherapie
DDC 610 / Medicine & health
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Cancers, Vol 12, Iss 3021, p 3021 (2020), Cancers, Volume 12, Issue 10
- Accession number :
- edsair.doi.dedup.....d0f76057f661a383408a7526761b3a4a